Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus modified CAG vs idarubicin plus cytarabine in elderly AML
ChiCTR2000035270Phase 3Completed
- Sponsor
- Southern Medical University
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of decitabine, idarubicin, cytarabine, aclarubicin and granulocyte colony-stimulating factor in acute myeloid leukemia (AML) (2 arms), sponsored by Southern Medical University. Primary endpoint: one-year overall survival. Started Jan 2015; status: completed.
02
Drugs
decitabineidarubicincytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000035270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035270.